- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04094610
En undersøgelse af repotrectinib hos pædiatriske og unge voksne, der rummer ALK-, ROS1- ELLER NTRK1-3-ændringer
A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE)
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D).
Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Enrollment of subjects into Phase 1 will proceed concurrently by age as follows:
- Subjects <12 years old will initially be enrolled in the Phase 1 part to determine the pediatric RP2D for this age group; once the pediatric RP2D is determined, subjects age <12 years old may be enrolled into the Phase 2 part of the study.
- Subjects 12 to 25 years old will be directly enrolled into the Phase 2 part concurrent with Phase 1 enrollment.
Phase 1:
Approximately 12 pediatric subjects with locally advanced or metastatic solid tumors, including a primary central nervous system (CNS) tumor, or anaplastic large cell lymphoma (ALCL), with disease progression or who are non-responsive or intolerant to available therapies and for which no standard or available curative therapy exists.
Phase 2:
Subjects will be enrolled in one of 3 cohorts as follows:
Cohort 1: approximately 15 subjects with solid tumors characterized by NTRK fusion, TRK tyrosine kinase inhibitor (TKI)-naïve, and centrally confirmed measurable disease at baseline.
Cohort 2: approximately 23 subjects with solid tumors characterized by NTRK fusion, TRK TKI-pretreated, and centrally confirmed measurable disease at baseline.
Cohort 3: approximately 23 subjects with solid tumors or ALCL characterized by other ALK/ROS1/NTRK alterations or NTRK fusions without centrally confirmed measurable disease not otherwise eligible for Cohort 1 or 2. As of the current protocol amendment, only patients with ROS1 alterations will be enrolled to this cohort.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 1
Udvidet adgang
Kontakter og lokationer
Studiekontakt
- Navn: First line of the email MUST contain NCT # and Site #.
Undersøgelse Kontakt Backup
- Navn: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Telefonnummer: 855-907-3286
- E-mail: Clinical.Trials@bms.com
Studiesteder
-
-
New South Wales
-
Randwick, New South Wales, Australien, 2031
- Rekruttering
- Local Institution - 6104
-
Kontakt:
- Site 6104
-
Westmead, New South Wales, Australien
- Afsluttet
- Local Institution - 6103
-
-
Queensland
-
South Brisbane, Queensland, Australien, 4101
- Rekruttering
- Children's Health Queensland Hospital and Health Service
-
Kontakt:
- Timothy Hassall, Site 6102
- Telefonnummer: 61730681111
-
-
Western Australia
-
Nedlands, Western Australia, Australien, 6009
- Rekruttering
- Perth Childrens Hospital
-
Kontakt:
- Nick Gottardo, Site 6101
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Rekruttering
- University Of Calgary
-
Kontakt:
- Victor Lewis, Site 2202
- Telefonnummer: 14039557203
-
Edmonton, Alberta, Canada, T6G 2B7
- Rekruttering
- Stollery Children'S Hospital
-
Kontakt:
- Sunil desai, Site 2201
- Telefonnummer: 17802485415
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L1
- Rekruttering
- Children'S Hospital Of Eastern Ontario
-
Kontakt:
- Lesleigh Abbott, Site 2203
- Telefonnummer: 61373776002370
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C5
- Rekruttering
- St Justine Hospital
-
Kontakt:
- Sebastien Perreault, Site 2205
- Telefonnummer: 4384958893
-
-
-
-
-
Copenhagen, Danmark, 2100
- Rekruttering
- Rigshospitalet - Glostrup
-
Kontakt:
- Karsten Nysom, Site 4901
- Telefonnummer: 4535450809
-
-
-
-
-
Birmingham, Det Forenede Kongerige, B4 6DH
- Afsluttet
- Local Institution - 4403
-
Cardiff, Det Forenede Kongerige, CF14 4XW
- Rekruttering
- University Hospital of Wales
-
Kontakt:
- Madeleine Adams, Site 4401
- Telefonnummer: 02920742107
-
Glasgow, Det Forenede Kongerige, G51 4TF
- Rekruttering
- Royal Hosp. for Children
-
Kontakt:
- Milind Ronghe, Site 4406
-
London, Det Forenede Kongerige, SW3 6JJ
- Rekruttering
- The Royal Marsden NHS Foundation Trust
-
Kontakt:
- Linley Marchall, Site 4405
- Telefonnummer: 209156161
-
London, Det Forenede Kongerige, WC1N 3JH
- Rekruttering
- Great Ormond Street Hospital For Children NHS Foundation Trust
-
Kontakt:
- Elwira Szychot, Site 4402
- Telefonnummer: 447849760509
-
-
England
-
Liverpool, England, Det Forenede Kongerige, L12 2AP
- Rekruttering
- Alder Hey Children's NHS Foundation Trust
-
Kontakt:
- Lisa Howell, Site 4404
- Telefonnummer: +441512933679
-
-
-
-
California
-
Los Angeles, California, Forenede Stater, 90095
- Rekruttering
- University of California at Los Angeles
-
Kontakt:
- Noah Federman, Site 2109
- Telefonnummer: 310-206-7625
-
Los Angeles, California, Forenede Stater, 90027-6062
- Rekruttering
- Children's Hospital Los Angeles
-
Kontakt:
- Leo Mascarenhas, Site 2111
- Telefonnummer: 323-361-5418
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- Children's Hospital Colorado - Anschutz Medical Campus
-
Kontakt:
- Margaret Macy, Site 2108
- Telefonnummer: 720-777-8856
-
-
Florida
-
Orlando, Florida, Forenede Stater, 32827
- Afsluttet
- Local Institution - 2120
-
Orlando, Florida, Forenede Stater, 32806
- Afsluttet
- Local Institution - 2105
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30329
- Rekruttering
- Children's Healthcare of Atlanta - Egleston Hospital
-
Kontakt:
- Tobey Macdonald, Site 2119
- Telefonnummer: 000-000-0000
-
-
Maine
-
Scarborough, Maine, Forenede Stater, 04074
- Rekruttering
- Maine Medical Center
-
Kontakt:
- Stanley Chaleff, Site 2115
- Telefonnummer: 207-396-7565
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Dana Farber Cancer Institute.
-
Kontakt:
- Steven Dubois, Site 2106
- Telefonnummer: 415-476-3831
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University School of Medicine in St. Louis
-
Kontakt:
- Andrew Cluster, Site 2113
- Telefonnummer: 443-745-4180
-
-
New Jersey
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Afsluttet
- Local Institution - 2110
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Afsluttet
- Local Institution - 2102
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28203
- Rekruttering
- Levine Children's Hospital- Pediatric Neuro-Oncology
-
Kontakt:
- Chad Jacobsen, Site 2121
- Telefonnummer: 000-000-0000
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Afsluttet
- Local Institution - 2112
-
-
Pennsylvania
-
Hershey, Pennsylvania, Forenede Stater, 17033
- Afsluttet
- Local Institution - 2114
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research
-
Kontakt:
- Theodore Laetsch, Site 2117
- Telefonnummer: 267-425-5544
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38015
- Rekruttering
- St. Jude Children's Research Hospital
-
Kontakt:
- Alberto Pappo, Site 2103
- Telefonnummer: 901-595-3300
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75390
- Rekruttering
- The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center
-
Kontakt:
- Tanya Carens Watt, Site 2101
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Baylor College of Medicine
-
Kontakt:
- Matthew McEvoy, Site 2118
-
Houston, Texas, Forenede Stater, 77030
- Afsluttet
- Local Institution - 2104
-
-
Virginia
-
Richmond, Virginia, Forenede Stater, 23219
- Trukket tilbage
- Children's Hospital of Richmond at VCU
-
-
-
-
-
Angers, Frankrig, 49933
- Rekruttering
- Centre Hospitalier Universitaire D'Angers
-
Kontakt:
- Emilie De Carli, Site 4203
- Telefonnummer: 0241353863
-
Bordeaux, Frankrig, 33076
- Rekruttering
- Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Pellegrin
-
Kontakt:
- Stephane Ducassou, Site 4201
- Telefonnummer: 0557820438
-
Lyon, Frankrig, 69373
- Rekruttering
- Institut d Hematologie et d Oncologie Pediatriques
-
Kontakt:
- Nadege Corradini, Site 4204
- Telefonnummer: 33478782642
-
Marseille, Frankrig, 13385
- Rekruttering
- Hôpitaux Universitaires de Marseille Timone
-
Kontakt:
- Nicolas Andre, Site 4205
- Telefonnummer: 33491386821
-
Marseille, Frankrig, 13385
- Ikke rekrutterer endnu
- Local Institution - 6110
-
Kontakt:
- Site 6110
-
Nantes, Frankrig, 44093
- Ikke rekrutterer endnu
- Local Institution - 6112
-
Kontakt:
- Site 6112
-
Paris, Frankrig, 75005
- Ikke rekrutterer endnu
- Local Institution - 6109
-
Kontakt:
- Site 6109
-
Villejuif, Frankrig, 94805
- Ikke rekrutterer endnu
- Local Institution - 6108
-
Kontakt:
- Site 6108
-
Villejuif, Frankrig, 94805
- Rekruttering
- Institut Gustave-Roussy
-
Kontakt:
- Samuel Abbou, Site 4202
- Telefonnummer: 142114211
-
-
Rhone
-
Lyon, Rhone, Frankrig, 69008
- Ikke rekrutterer endnu
- Local Institution - 6111
-
Kontakt:
- Site 6111
-
-
-
-
-
Milan, Italien, 20133
- Rekruttering
- Fondazione IRCCS - Istituto Nazionale dei Tumori
-
Kontakt:
- Michela Casanova, Site 4301
- Telefonnummer: 390223902593
-
Padova, Italien, 35128
- Trukket tilbage
- Local Institution - 6113
-
Rome, Italien, 00165
- Ikke rekrutterer endnu
- Local Institution - 4302
-
Kontakt:
- Site 4302
-
Torino, Italien, 10126
- Trukket tilbage
- Local Institution - 6114
-
-
-
-
-
Singapore, Singapore, 229899
- Rekruttering
- KK Women's and Children's Hospital
-
Kontakt:
- Shui Yen Soh, Site 6402
- Telefonnummer: 6563941045
-
Singapore, Singapore, 119228
- Rekruttering
- National University Hospital
-
Kontakt:
- Allen Yeoh, Site 6401
- Telefonnummer: 67724406
-
-
-
-
-
Barcelona, Spanien, 8035
- Rekruttering
- Hospital Universitari Vall d'Hebron
-
Kontakt:
- Maria Paula Perez Albert, Site 4103
-
Barcelona, Spanien, 08014
- Ikke rekrutterer endnu
- Local Institution - 6105
-
Kontakt:
- Site 6105
-
Madrid, Spanien, 28009
- Rekruttering
- Hospital Infantil Universitario Nino Jesus
-
Kontakt:
- Alvaro Lassaletta, Site 4105
- Telefonnummer: +34915035938
-
Madrid, Spanien, 28022
- Rekruttering
- Clinica Universidad de Navarra
-
Kontakt:
- Elena Panizo Morgado, Site 4101
- Telefonnummer: 34913531920
-
Madrid, Spanien, 28009
- Ikke rekrutterer endnu
- Local Institution - 6106
-
Kontakt:
- Site 6106
-
Madrid, Spanien, 28050
- Rekruttering
- HM Sanchinarro University Hospital
-
Kontakt:
- Marta Osuna Marco, Site 4104
- Telefonnummer: 34917089935
-
Seville, Spanien, 41013
- Rekruttering
- Hospital Universitario Virgen del Rocio
-
Kontakt:
- Jose Luis Moreno, Site 4108
- Telefonnummer: 955012000
-
Valencia, Spanien, 46026
- Ikke rekrutterer endnu
- Local Institution - 6107
-
Kontakt:
- Site 6107
-
Valencia, Spanien, 46026
- Rekruttering
- Hospital Universitario Y Politecnico La Fe
-
Kontakt:
- Antonio Juan Ribelles, Site 4107
- Telefonnummer: 961244190
-
-
Barcelona
-
Esplugues de Llobregat, Barcelona, Spanien, 08950
- Rekruttering
- Hospital Sant Joan De Deu
-
Kontakt:
- Alicia Castaneda Heredia, Site 4106
- Telefonnummer: 34932532100
-
-
Navarre
-
Pamplona, Navarre, Spanien, 31008
- Rekruttering
- Clínica Universidad de navarra
-
Kontakt:
- Elena Panizo Morgado, Site 4102
- Telefonnummer: 34913531920
-
-
-
-
-
Seoul, Sydkorea, 05505
- Rekruttering
- Asan Medical Center
-
Kontakt:
- Kyung Nam Koh, Site 6302
- Telefonnummer: +82230105994
-
Seoul, Sydkorea, 03080
- Rekruttering
- Seoul National University Hospital
-
Kontakt:
- Hyoung Jin Kang, Site 6301
- Telefonnummer: 82220723304
-
Seoul, Sydkorea, 06351
- Afsluttet
- Local Institution - 6304
-
-
Seodaemun-gu
-
Seoul, Seodaemun-gu, Sydkorea, 03722
- Afsluttet
- Local Institution - 6303
-
-
-
-
-
Taipei, Taiwan, 11031
- Rekruttering
- Taipei Medical University Hospital
-
Kontakt:
- Yen-Lin Liu, Site 6201
- Telefonnummer: 886970749572
-
Taipei, Taiwan, 100225
- Afsluttet
- Local Institution - 6202
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Documented genetic ROS1 point mutation, fusion, or amplification or NTRK1-3 fusion as identified by local testing in a Clinical Laboratory Improvement Amendments (CLIA) laboratory in the US or equivalently accredited diagnostic lab outside the United States (US) is required.
- Phase 1: Age <12 years; Phase 2: Age 12- 25 years
- Prior cytotoxic chemotherapy is allowed.
- Prior immunotherapy is allowed.
- Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.
- All subjects must have measurable disease by RECIST v1.1 or Response Assessment in Neuro-Oncology (RANO) criteria at time of enrollment.
- Subjects with a primary CNS tumor or CNS metastases must be neurologically stable on a stable or decreasing dose of steroids for at least 7 days prior to enrollment.
- Subjects must have a Lansky (< 16 years) or Karnofsky (≥ 16 years) score of at least 50.
- Life expectancy greater than or equal to 12 weeks, in the investigator's opinion.
- Adequate hematologic, renal and hepatic function.
Phase 2 Inclusion Criteria:
-
Cohort Specific Inclusion Criteria:
- Cohort 1: Subjects with NTRK fusion gene positive (NTRK+) advanced solid tumors (including primary CNS tumors), that are tropomyosin receptor kinase (TRK) TKI naïve;
- Cohort 2: subjects with NTRK+ advanced solid tumors (including primary CNS tumors), that are TRK TKI pre-treated;
- Cohort 3: subjects with advanced solid tumors with ROS1 gene fusions or other ROS1 aberrations (including amplifications and point mutations) with measurable disease.
-
Subjects in Cohorts 1 and 2 must have prospectively confirmed measurable disease by BICR prior to enrollment.
Key Exclusion Criteria (Phase 1 and Phase 2):
-
Subjects with neuroblastoma with only bone marrow disease evaluable by bone marrow aspiration only.
-
Major surgery within 14 days (2 weeks) of start of repotrectinib treatment. Central venous access (Broviac, Mediport, etc.) placement does not meet criteria for major surgery.
-
Known active infections requiring ongoing treatment (bacterial, fungal, viral including HIV positivity).
-
Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.
-
Any of the following cardiac criteria:
- Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTc) > 480 msec obtained from three ECGs, using the screening clinic ECG machine-derived QTc value
- Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec)
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval
-
Peripheral neuropathy of CTCAE ≥grade 2.
-
Subjects being treated with or anticipating the need for treatment with strong CYP3A4 inhibitors or inducers.
-
Any potential allergies to repotrectinib and/or its excipients.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Repotrectinib (TPX-0005)
Phase 1 Oral repotrectinib (TPX-0005): Safety and tolerability at different dose levels Phase 2 Oral repotrectinib (TPX-0005): 3 cohorts Cohort 1: TKI-naive NTRK fusion Cohort 2: Prior TKI NTRK fusion Cohort 3: ROS1 gene fusions or other ROS1 aberrations |
Oral repotrectinib (TPX-0005)
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Dose limiting toxicities (DLTs) (Phase 1)
Tidsramme: Within 28 days of the first repotrectinib dose
|
Define the dose limiting toxicities (DLTs) (Phase 1) |
Within 28 days of the first repotrectinib dose
|
|
Pediatric Recommended Phase 2 Dose (RP2D) (Phase 1)
Tidsramme: Within 28 days of the last patient dosed in escalation
|
To determine the pediatric RP2D (Phase 1) |
Within 28 days of the last patient dosed in escalation
|
|
Overall Response Rate (ORR) (Phase 2)
Tidsramme: Two to three years after first dose of repotrectinib
|
To determine the confirmed ORR of repotrectinib (TPX-0005) as assessed by Blinded Independent Central Review (Phase 2) |
Two to three years after first dose of repotrectinib
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Response Rate (ORR) (Phase 1)
Tidsramme: Approximately three years
|
To determine the overall response rate (ORR) by Blinded Independent Central Review (BICR) (Phase 1) |
Approximately three years
|
|
Clinical Benefit Rate (CBR) (Phase 1 and Phase 2)
Tidsramme: Approximately three years
|
To determine the CBR of repotrectinib (TPX-0005) (Phase 1 and Phase 2) |
Approximately three years
|
|
Time to response (TTR) (Phase 1 and Phase 2)
Tidsramme: Approximately three years
|
To determine the TTR of reprotrectinib (TPX-005) (Phase 1 and Phase 2) |
Approximately three years
|
|
Duration of response (DOR) (Phase 1 and Phase 2)
Tidsramme: Approximately three years
|
To determine the DOR of repotrectinib (TPX-0005) (Phase 1 and Phase 2) |
Approximately three years
|
|
Intracranial objective response rate (IC-ORR) (Phase 1 and Phase 2)
Tidsramme: Approximately three years
|
To determine the IC-ORR of repotrectinib in subjects with measurable brain metastases (TPX-005) (Phase 1 and Phase 2) |
Approximately three years
|
|
Central Nervous System Progression-Free Survival (CNS-PFS) (Phase 2)
Tidsramme: Approximately three years
|
CNS-PFS in subjects with measurable brain metastases (Phase 2) |
Approximately three years
|
|
Progression-free survival (PFS) (Phase 2)
Tidsramme: Approximately three years
|
To determine the PFS (Phase 2) |
Approximately three years
|
|
Overall survival (OS) (Phase 2)
Tidsramme: Approximately three years
|
To determine the OS (Phase 2) |
Approximately three years
|
|
Maximum concentration of repotrectinib in plasma (Cmax)
Tidsramme: Pre-dose and up to 24 hours post-dose on Day 1 and Day 15 in Cycle 1 (each cycle is 28 days)
|
To determine the Cmax |
Pre-dose and up to 24 hours post-dose on Day 1 and Day 15 in Cycle 1 (each cycle is 28 days)
|
|
Area under the concentration versus time curve of repotrectinib in plasma (AUC)
Tidsramme: Pre-dose and up to 24 hours post-dose on Day 1 and Day 15 in Cycle 1 (each cycle is 28 days)
|
To determine the AUC |
Pre-dose and up to 24 hours post-dose on Day 1 and Day 15 in Cycle 1 (each cycle is 28 days)
|
|
Number of participants with laboratory abnormalities
Tidsramme: Approximately three years
|
Approximately three years
|
|
|
Number of Participants with Adverse events
Tidsramme: Approximately three years
|
Approximately three years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Bristol-Myers Squibb, Bristol-Myers Squibb
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Neoplasmer
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Neoplastiske processer
- Lymfesygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom, Non-Hodgkin
- Astrocytom
- Neoplasmer, Neuroepithelial
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Neoplasmer, bindevæv og blødt væv
- Neoplasmer, bindevæv
- Granulom
- Neoplasmer, fibrøst væv
- Lymfom, T-celle
- Patologiske tilstande, tegn og symptomer
- Hemiske og lymfatiske sygdomme
- Lymfom
- Neoplasma Metastase
- Glioblastom
- Gliom
- Sarkom
- Lymfom, storcellet, anaplastisk
- Solitære fibrøse tumorer
- Granulom, plasmacelle
- Farmaceutiske præparater
- Doseringsformer
- Komplekse blandinger
- Kolloider
- Repotrectinib
- Suspensioner
- Kapsler
Andre undersøgelses-id-numre
- CA127-1029
- TPX-0005-07 (Anden identifikator: Turning Point Therapeutics Protocol ID)
- CA127-1029 (Anden identifikator: BMS Protocol ID)
- 2023 (U.S. NIH-bevilling/kontrakt)
- 2023-506464-14 (Anden identifikator: EU CTR)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
IPD-delingstidsramme
See Plan Description
IPD-delingsadgangskriterier
See Plan Description
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .